Aiming for 9% Market Share This Year

Hugel announced the official entry of its botulinum toxin "Letybo" into the Indian market by participating in the Global Aesthetic Summit (GAS) held in Goa, India.


Hugel stated that this event was held at the TAJ Horizon in Goa, India, from July 19 to July 21.

Hugel participated in the GAS conference on the 20th and introduced the clinical strengths of Letibo. Hugel

Hugel participated in the GAS conference on the 20th and introduced the clinical strengths of Letibo. Hugel

View original image

India, with a population of approximately 1.5 billion, is one of the largest markets in the world, and as the middle class rapidly expands, demand for aesthetic medicine is increasing. However, the rate of botulinum toxin procedures remains low compared to the total population, making India a market with significant growth potential. Hugel has set a goal of achieving a 9% market share in the Indian aesthetic market this year.


At the GAS conference, Hugel worked with its local distributor, Aakaar Medical, to raise brand awareness and build a Key Opinion Leader (KOL) network. Australian KOL Benjamin Chan, who served as a speaker, introduced Letybo's "Narrow Diffusion" characteristic, which enables predictable procedure outcomes.


Until July 24, Hugel plans to hold separate launch events and hands-on workshops with its local distributor. The company then aims to strengthen its position in the Indian market by expanding academic exchanges with KOLs, while leveraging these activities to enhance Letybo's presence in the Asia-Pacific and global markets.



Jang Doohyun, CEO of Hugel, said, "India is a market with a very high preference for and interest in 'K-Aesthetic,' and we plan to actively utilize Hugel's strengths as Korea's number one toxin brand for 10 consecutive years in our marketing efforts. We aim to drive the expansion of the Indian market and secure new global growth engines."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing